Journal
JOURNAL OF BIOSCIENCES
Volume 43, Issue 5, Pages 1015-1023Publisher
INDIAN ACAD SCIENCES
DOI: 10.1007/s12038-018-9805-y
Keywords
Biomarker; GIST; miR-518e-5p; secondary imatinib resistance; serum
Categories
Ask authors/readers for more resources
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the intestinal tract. Imatinib is used as first-line therapy for GIST patients; however, secondary imatinib resistance poses a significant clinical challenge. Here, we analyzed serum miRNA expression profiles to identify specific serum miRNAs that could be used as early diagnostic markers. Candidate miRNAs were validated using Taqman quantitative PCR with serum samples from secondary imatinib-resistant GIST patients (n=39), imatinib-sensitive GIST patients (n=37), and healthy controls (n=28). Serum miR-518e-5p and miR-548e levels were higher in secondary imatinib-resistant GIST than imatinib-sensitive GIST patients or healthy controls (P<0.0001). However, ROC analysis indicated that only miR-518e-5p could distinguish imatinib-resistant GIST. To discriminate imatinib-resistant from imatinib-sensitive GIST patients, the AUC for serum miR-518e-5p was 0.9938, with 99.8% sensitivity and 82.1% specificity. Serum miR-518e-5p could also discriminate imatinib-resistant GIST patients from healthy controls with 99.9% sensitivity and 97.4% specificity. These data indicate that serum miR-518e-5p is a potentially promising non-invasive biomarker for early detection and diagnosis of secondary imatinib-resistant GIST.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available